Staphylococcus aureus virulence factors in evasion from innate immune defenses in human and animal diseases

Immunology Letters

Volumn 150, Issue 1-2, 2013, Pages 12-22

  Zecconi, Alfonso ^a   Scali, Federico ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Adhesins; Host defense peptides; Innate immunity; Staphylococcus aureus; TLR

Indexed keywords

CATHELICIDIN; GAMMA INTERFERON; INTERLEUKIN 2; POLYPEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; CYTOKINE PRODUCTION; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNE EVASION; IMMUNOMODULATION; INNATE IMMUNITY; MASTITIS; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; VETERINARY MEDICINE;

ANIMAL DISEASES; ANIMALS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VIRULENCE FACTORS;

EID: 84874418889     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.01.004     Document Type: Review

References (200)

1. Al-Dabbagh M., Dobson S. Infectious hazards from pets and domestic animals. Hot topics in infection and immunity in children Vii 2011, 261-272. N. Curtis, A. Finn, A.J. Pollard (Eds.).
2. Fluit A.C. Livestock-associated Staphylococcus aureus. Clin Microbiol Infect 2012, 18:735-744.
3. Hasman H., Moodley A., Guardabassi L., Stegger M., Skov R.L., Aarestrup F.M. spa type distribution in Staphylococcus aureus originating from pigs, cattle and poultry. Vet Microbiol 2010, 141:326-331.
4. Vanderhaeghen W., Hermans K., Haesebrouck F., Butaye P. Methicillin-resistant Staphylococcus aureus (MRSA) in food production animals. Epidemiol Infect 2010, 138:606-625.
5. Goetghebeur M., Landry P.A., Han D., Vicente C. Methicillin-resistant Staphylococcus aureus: a public health issue with economic consequences. Can J Infect Dis Med Microbiol 2007, 18:27-34.
6. McCaig L.F., McDonald L.C., Mandal S., Jernigan D.B. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis 2006, 12:1715-1723.
7. Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298:1763-1771.
8. Leonard F.C., Markey B.K. Meticillin-resistant Staphylococcus aureus in animals: a review. Vet J 2008, 175:27-36.
9. Rich M. Staphylococci in animals: prevalence, identification and antimicrobial susceptibility, with an emphasis on methicillin-resistant Staphylococcus aureus. Br J Biomed Sci 2005, 62:98-105.
10. Zecconi A. Staphylococcus aureus mastitis: what we need to know to control them. Isr J Vet Med 2010, 65:93-99.
11. Zecconi A., Calvinho L.F., Fox K.L. Staphylococcus aureus intramammary infections. IDF Bull 2006, 408:1-42.
12. Piccinini R., Borromeo V., Zecconi A. Relationship between S. aureus gene pattern and dairy herd mastitis prevalence. Vet Microbiol 2010, 145:100-105.
13. Barber M. Methicillin-resistant staphylococci. J Clin Pathol 1961, 14:385-393.
14. Boyce J.M. Methicillin-resistant Staphylococcus aureus in hospital and long-tem care facilities - microbiology, epidemiology, and preventive measures. Infect Control Hosp Epidemiol 1992, 13:725-737.
15. Johnson A.P., Aucken H.M., Cavendish S., Ganner M., Wale M.C.J., Warner M., et al. Dominance of EMRSA-15 and-16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS). J Antimicrob Chemother 2001, 48:143-144.
16. Bukharie H.A., Abdelhadi M.S., Saeed I.A., Rubaish A.M., Larbi E.B. Emergence of methicillin-resistant Staphylococcus aureus as a community pathogen. Diagn Microbiol Infect Dis 2001, 40:1-4.
17. Salgado C.D., Farr B.M., Calfee D.P. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 2003, 36:131-139.
18. Devriese L.A., Van Damme L.R., Fameree L. Methicillin-(cloxacillin)-resistant Staphylococcus aureus strains isolated from bovine mastitis cases. Zentralbl Hyg Umweltmed 1972, 19:598-605.
19. Voss A., Loeffen F., Bakker J., Klaassen C., Wulf M. Methicillin-resistant Staphylococcus aureus in pig farming. Emerg Infect Dis 2005, 11:1965-1966.
20. van Loo I., Huijsdens X., Tiemersma E., de Neeling A., van de Sande-Bruinsma N., Beaujean D., et al. Emergence of methicillin-resistant Staphylococcus aureus of animal origin in humans. Emerg Infect Dis 2007, 13:1834-1839.
21. Khanna T., Friendship R., Dewey C., Weese J.S. Methicillin resistant Staphylococcus aureus colonization in pigs and pig farmers. Vet Microbiol 2008, 128:298-303.
22. Calfee D.P. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, and other Gram-positives in healthcare. Curr Opin Investig Drugs 2012, 25:385-394.
23. Petinaki E., Spiliopoulou I. Methicillin-resistant Staphylococcus aureus among companion and food-chain animals: impact of human contacts. Clin Microbiol Infect 2012, 18:626-634.
24. Fitzgerald J.R. Livestock-associated Staphylococcus aureus: origin, evolution and public health threat. Trends Microbiol 2012, 20:192-198.
25. Stefani S., Chung D.R., Lindsay J.A., Friedrich A.W., Kearns A.M., Westh H., et al. Meticillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonisation of typing methods. Int J Antimicrob Agents 2012, 39:273-282.
26. Gould I.M., David M.Z., Esposito S., Garau J., Lina G., Mazzei T., et al. New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents 2012, 39:96-104.
27. Skov R., Christiansen K., Dancer S.J., Daum R.S., Dryden M., Huang Y.C., et al. Update on the prevention and control of community-acquired meticillin-resistant Staphylococcus aureus (CA-MRSA). Int J Antimicrob Agents 2012, 39:193-200.
28. Lowy F.D. Medical progress - Staphylococcus aureus infections. N Engl J Med 1998, 339:520-532.
29. Kluytmans J., vanBelkum A., Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997, 10:505.
30. Zecconi A., Cesaris L., Liandris E., Daprà V., Piccinini R. Role of several Staphylococcus aureus virulence factors on the inflammatory response in bovine mammary gland. Microb Pathog 2006, 40:177-183.
31. Taverna F., Negri A., Piccinini R., Zecconi A., Nonnis S., Ronchi S., et al. Characterization of cell wall associated proteins of a Staphylococcus aureus isolated from bovine mastitis case by a proteomic approach. Vet Microbiol 2007, 119:240-247.
32. Kerro Dego O., van Dijk J., Nederbragt H. Factors involved in the early pathogenesis of bovine Staphylococcus aureus mastitis with emphasis on bacterial adhesion and invasion. A review. Vet Q 2002, 24:181-198.
33. Sutra L., Poutrel B. Virulence factors involved in the pathogenesis of bovine intramammary infections due to Staphylococcus aureus. J Med Microbiol 1994, 40(2):79-89.
34. Fox L.K., Gershaman M., Hancock D.D., Hutton C.T. Fomities and reservoirs of S. aureus causing intramammary infections as determined by phage typing: the effect of milking hygiene practises. Cornell Vet 1990, 81:183-193.
35. Robertson J.R., Fox L.K., Hancock D.D., Gay J.M., Besser T.E. Sources of intramammary infections from Staphylococcus aureus in dairy heifers at first parturition. J Dairy Sci 1998, 81:687-693.
36. Rainard P., Riollet C. Innate immunity of the bovine mammary gland. Vet Res 2006, 37:369-400.
37. Rinaldi M., Li R.W., Bannerman D.D., Daniels K.M., Evock-Clover C., Silva M.V.B., et al. A sentinel function for teat tissues in dairy cows: dominant innate immune response elements define early response to E. coli mastitis. Funct Integr Genomics 2010, 10:21-38.
38. Riollet C., Rainard P., Poutrel B. Cells and cytokines in inflammatory secretions of bovine mammary gland. Adv Exp Med Biol 2000, 480:247-258.
39. Zecconi A., Smith K.L. Ruminant mammary gland immunity 2003, FIL-IDF, Bruxelles.
40. Watson D. Staphylococcal mastitis vaccine. Vaccine 1992, 10(5):359.
41. Leitner G., Lubashevsky E., Trainin Z. Staphylococcus aureus vaccine against mastitis in dairy cows, composition and evaluation of its immunogenicity in a mouse model. Vet Immunol Immunopathol 2003, 93:159-167.
42. Pellegrino M., Giraudo J., Raspanti C., Odierno L., Bogni C. Efficacy of immunization against bovine mastitis using a Staphylococcus aureus avirulent mutant vaccine. Vaccine 2010, 28:4523-4528.
43. Castagliuolo I., Piccinini R., Beggiao E., Palù G., Mengoli C., Ditadi F., et al. Mucosal genetic immunization against four adhesins protects against Staphylococcus aureus-induced mastitis. Vaccine 2006, 24:4393-4402.
44. Scarpa M., Piccinini R., Brun P., Grillo A., Palu G., Mengoli C., et al. Relationship between virulence factor genes in bovine Staphylococcus aureus subclinical mastitis isolates and binding to anti-adhesin antibodies. J Dairy Res 2010, 77:159-167.
45. Pereira U.P., Oliveira D.G.S., Mesquita L.R., Costa G.M., Pereira U. Efficacy of Staphylococcus aureus vaccines for bovine mastitis: a systematic review. Vet Microbiol 2011, 148:117-124.
46. Middleton J.R. Staphylococcus aureus antigens and challenges in vaccine development. Expert Rev Vac 2008, 7:805-815.
47. Middleton J.R., Luby C.D., Adams D.S. Efficacy of vaccination against staphylococcal mastitis: a review and new data. Vet Microbiol 2009, 134:192-198.
48. Fedtke I., Gotz F., Peschel A. Bacterial evasion of innate host defenses - the Staphylococcus aureus lesson. Int J Med Microbiol 2004, 294:189-194.
49. Rooijakkers S.H.M., van Kessel K.P.M., van Strijp J.A.G. Staphylococcal innate immune evasion. Trends Microbiol 2005, 13:596-601.
50. Urban C.F., Lourido S., Zychlinsky A. How do microbes evade neutrophil killing. Cell Microbiol 2006, 8:1687-1696.
51. Graves S.F., Kobayashi S.D., DeLeo F.R. Community-associated methicillin-resistant Staphylococcus aureus immune evasion and virulence. J Mol Med 2010, 88:109-114.
52. Peacock S.J., Moore C.E., Justice A., Kantzanou M., Story L., Mackie K., et al. Virulent combinations of adhesin and toxin genes in natural populations of Staphylococcus aureus. Infect Immun 2002, 70:4987-4996.
53. Chavakis T., Preissner K.T., Herrmann M. The anti-inflammatory activities of Staphylococcus aureus. Trends Immunol 2007, 28:408-418.
54. DuMont A.L., Nygaard T.K., Watkins R.L., Smith A., Kozhaya L., Kreiswirth B.N., et al. Characterization of a new cytotoxin that contributes to Staphylococcus aureus pathogenesis. Mol Microbiol 2011, 79:814-825.
55. Perret M., Badiou C., Lina G., Burbaud S., Benito Y., Bes M., et al. Cross-talk between Staphylococcus aureus leukocidins-intoxicated macrophages and lung epithelial cells triggers chemokine secretion in an inflammasome-dependent manner. Cell Microbiol 2012, 14:1019-1036.
56. Kato F., Kadomoto N., Iwamoto Y., Bunai K., Komatsuzawa H., Sugai M. Regulatory mechanism for exfoliative toxin production in Staphylococcus aureus. Infect Immun 2011, 79:1660-1670.
57. Baker M.D., Acharya K.R. Superantigens structure-function relationships. Int J Med Microbiol 2004, 293:529-537.
58. Ortega E., Abriouel H., Lucas R., Galvez A. Multiple roles of Staphylococcus aureus enterotoxins: pathogenicity, superantigenic activity, and correlation to antibiotic resistance. Toxins 2010, 2.
59. Speziale P., Pietrocola G., Rindi S., Provenzano M., Provenza G., Di Poto A., et al. Structural and functional role of Staphylococcus aureus surface components recognizing adhesive matrix molecules of the host. Future Microbiol 2009, 4.
60. Clarke S.R., Foster S.J. Surface adhesins of Staphylococcus aureus. Adv Microb Physiol 2006, 51:51.
61. Arciola C.R., Visai L., Testoni F., Arciola S., Campoccia D., Speziale P., et al. Concise survey of Staphylococcus aureus virulence factors that promote adhesion and damage to peri-implant tissues. Int J Artif Organs 2011, 34:771-780.
62. Vazquez V., Liang X.W., Horndahl J.K., Ganesh V.K., Smeds E., Foster T.J., et al. Fibrinogen is a ligand for the Staphylococcus aureus microbial surface components recognizing adhesive matrix molecules (MSCRAMM) bone sialoprotein-binding protein (Bbp). J Biol Chem 2011, 286:29797-29805.
63. Geoghegan J.A., Corrigan R.M., Gruszka D.T., Speziale P., O'Gara J.P., Potts J.R., et al. Role of surface protein SasG in biofilm formation by Staphylococcus aureus. J Bacteriol 2010, 192.
64. Johnson M., Cockayne A., Morrissey J.A. Iron-regulated biofilm formation in Staphylococcus aureus Newman requires ica and the secreted protein Emp. Infect Immun 2008, 76:1756-1765.
65. Thompson K.M., Abraham N., Jefferson K.K. Staphylococcus aureus extracellular adherence protein contributes to biofilm formation in the presence of serum. FEMS Microbiol Lett 2010, 305:143-147.
66. Harraghy N., Hussain M., Haggar A., Chavakis T., Sinha B., Herrmann M., et al. The adhesive and immunomodulating properties of the multifunctional Staphylococcus aureus protein Eap. Microbiology-SGM 2003, 149:2701-2707.
67. Athanasopoulos A.N., Ecnomopoulou M., Orlova V.V., Sobke A., Schneider D., Weber H., et al. The extracellular adherence protein (Eap) of Staphylococcus aureus inhibits wound heating by interfering with host defense and repair mechanisms. Blood 2006, 107:2720-2727.
68. Edwards A.M., Bowden M.G., Brown E.L., Laabei M., Massey R.C. Staphylococcus aureus extracellular adherence protein triggers TNF alpha release, promoting attachment to endothelial cells via protein A. PLoS ONE 2012, 7:8.
69. Scriba T.J., Sierro S., Brown E.L., Phillips R.E., Sewell A.K., Massey R.C. The Staphyloccous aureus eap protein activates expression of proinflammatory cytokines. Infect Immun 2008, 76:2164-2168.
70. Haggar A., Ehrnfelt C., Holgersson J., Flock J.I. The extracellular adherence protein from Staphylococcus aureus inhibits neutrophil binding to endothelial cells. Infect Immun 2004, 72:6164-6167.
71. Sakamoto S., Tanaka Y., Tanaka I., Takei T., Yu J., Kuroda M., et al. Electron microscopy and computational studies of Ebh, a giant cell-wall-associated protein from Staphylococcus aureus. Biochem Biophys Res Commun 2008, 376:261-266.
72. Smith E.J., Corrigan R.M., van der Sluis T., Gruendling A., Speziale P., Geoghegan J.A., et al. The immune evasion protein Sbi of Staphylococcus aureus occurs both extracellularly and anchored to the cell envelope by binding lipoteichoic acid. Mol Microbiol 2012, 83.
73. Koch T.K., Reuter M., Barthel D., Böhm S., van den Elsen J., Kraiczy P., et al. Staphylococcus aureus proteins Sbi and Efb recruit human plasmin to degrade complement C3 and C3b. PLoS ONE 2012, 7:e47638.
74. McAdow M., Missiakas D.M., Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun 2012, 4:141-148.
75. Gordon R.J., Lowy F.D. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008, 46:S350-S359.
76. Thurlow L.R., Joshi G.S., Richardson A.R. Virulence strategies of the dominant USA300 lineage of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). FEMS Immunol Med Microbiol 2012, 65:5-22.
77. Urushibara N., Kawaguchiya M., Kobayashi N. Two novel arginine catabolic mobile elements and staphylococcal chromosome cassette mec composite islands in community-acquired methicillin-resistant Staphylococcus aureus genotypes ST5-MRSA-V and ST5-MRSA-II. J Antimicrob Chemother 2012, 67:1828-1834.
78. Medzhitov R., Janeway C.J. Advances in immunology: innate immunity. N Engl J Med 2000, 343:338-344.
79. Fournier B., Philpott D.J. Recognition of Staphylococcus aureus by the innate immune system. Clin Microbiol Rev 2005, 18:521-540.
80. López-Boado Y.S., Rubin B.K. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Pharmacol 2008, 8:286-291.
81. Ganz T. Antimicrobial polypeptides in host defense of the respiratory tract. J Clin Invest 2002, 109:693-697.
82. Fitzgerald D.C., Meade K.G., McEvoy A.N., Lillis L., Murphy E.P., Machugh D.E., et al. Tumour necrosis factor-alpha (TNF-alpha) increases nuclear factor kappaB (NFkappaB) activity in and interleukin-8 (IL-8) release from bovine mammary epithelial cells. Vet Immunol Immunopathol 2007, 116:59-68.
83. Didier A., Kessel S. Novel in-vitro co-culture system for studies on leukocyte-mammary gland epithelial cell cross-talk. Milchwissenschaft-Milk Sci Int 2004, 59:236-239.
84. Piccinini R., Binda E., Belotti M., Daprà V., Zecconi A. Evaluation of milk components during whole lactation in healthy quarters. J Dairy Res 2007, 74:226-232.
85. Piccinini R., Bronzo V., Moroni P., Luzzago C., Zecconi A. Study on the relationship between milk immune factors and Staphylococcus aureus intramammary infections in dairy cows. J Dairy Res 1999, 66:501-510.
86. Niwa Y., Sakane T., Yokoyama M., Shosey J.L., Miyachi Y. Reverse relationship between lysosomal-enzyme release and active-oxygen generation in stimulated human neutrophils. MolImmunol 1985, 22:973-980.
87. Paape M.J., Capuco A.V., Nickerson S.C., Dulin A.M. Effects of neutrophils on lactating mammary tissue. J Dairy Sci 1984, 67(1):95-96.
88. Alluwaimi A.M., Cullor J.S. Cytokines gene expression patterns of bovine milk during middle and late stages of lactation. J Vet Med Ser B-Infect Dis Vet Publ Health 2002, 49:105-110.
89. Kumar H., Kawai T., Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011, 30:16-34.
90. Garzoni C., Kelley W.L. Return of the Trojan horse: intracellular phenotype switching and immune evasion by Staphylococcus aureus. EMBO Mol Med 2011, 3:115-117.
91. van Belkum A. Staphylococcal colonization and infection: homeostasis versus disbalance of human (innate) immunity and bacterial virulence. Curr Opin Investig Drugs 2006, 19:339-344.
92. Broker B.M., van Belkum A. Immune proteomics of Staphylococcus aureus. Proteomics 2011, 11:3221-3231.
93. Foster T.J. Immune evasion by Staphylococci. Nat Rev Microbiol 2005, 3:948-958.
94. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637-650.
95. Yang R.B., Mark M.R., Gray A., Huang A., Xie M.H., Zhang M., et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 1998, 395:284-288.
96. Kirschning C.J., Wesche H., Ayres T.M., Rothe M. Human Toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. J Exp Med 1998, 188:2091-2097.
97. Schwandner R., Dziarski R., Wesche H., Rothe M., Kirschning C.J. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2. J Biol Chem 1999, 274:17406-17409.
98. Yoshimura A., Lien E., Ingalls R.R., Tuomanen E., Dziarski R., Golenbock D. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 1999, 163:1-5.
99. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
100. Blander J.M., Medzhitov R. Regulation of phagosome maturation by signals from Toll-like receptors. Science 2004, 304:1014-1018.
101. Watanabe I., Ichiki M., Shiratsuchi A., Nakanishi Y. TLR2-mediated survival of Staphylococcus aureus in macrophages: a novel bacterial strategy against host innate immunity. J Immunol 2007, 178:4917-4925.
102. Gonzalez-Zorn B., Senna J.P.M., Fiette L., Shorte S., Testard A., Chignard M., et al. Bacterial and host factors implicated in nasal carriage of methicillin-resistant Staphylococcus aureus in mice. Infect Immun 2005, 73:1847-1851.
103. Sun Y., Hise A.G., Kaisow C.M., Pearlman E. Staphylococcus aureus-induced corneal inflammation is dependent on Toll-like receptor 2 and myeloid differentiation factor 88. Infect Immun 2006, 74:5325-5332.
104. Hoebe K., Georgel P., Rutschmann S., Du X., Mudd S., Crozat K., et al. CD36 is a sensor of diacylglycerides. Nature 2005, 433:523-527.
105. Takeuchi O., Hoshino K., Kawai T., Sanjo H., Takada H., Ogawa T., et al. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 1999, 11:443-451.
106. Hoshino K., Takeuchi O., Kawai T., Sanjo H., Ogawa T., Takeda Y., et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999, 162:3749-3752.
107. Raetz C.R.H., Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem 2002, 71:635-700.
108. Stenzel W., Soltek S., Sanchez-Ruiz M., Akira S., Miletic H., Schluter D., et al. Both TLR2 and TLR4 are required for the effective immune response in Staphylococcus aureus-induced experimental murine brain abscess. Am J Pathol 2008, 172:132-145.
109. Inden K., Kaneko J., Miyazato A., Yamamoto N., Mouri S., Shibuya Y., et al. Toll-like receptor 4-dependent activation of myeloid dendritic cells by leukocidin of Staphylococcus aureus. Microbes Infect 2009, 11:245-253.
110. Parker D., Soong G. Induction of IFN-beta signaling by Staphylcoccus aureus USA300 is mediated by TLR9. Cytokine 2011, 56:92.
111. Franchi L., Wamer N., Viani K., Nunez G. Function of Nod-like receptors in microbial recognition and host defense. Immunol Rev 2009, 227:106-128.
112. Fritz J.H., Ferrero R.L., Philpott D.J., Girardin S.E. Nod-like proteins in immunity, inflammation and disease. Nat Immunol 2006, 7:1250-1257.
113. Girardin S.E., Boneca I.G., Carneiro L.A.M., Antignac A., Jehanno M., Viala J., et al. Nod1 detects a unique muropeptide from Gram-negative bacterial peptidoglycan. Science 2003, 300:1584-1587.
114. Chamaillard M., Hashimoto M., Horie Y., Masumoto J., Qiu S., Saab L., et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 2003, 4:702-707.
115. Girardin S.E., Boneca I.G., Viala J., Chamaillard M., Labigne A., Thomas G., et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003, 278:8869-8872.
116. Inohara N., Ogura Y., Fontalba A., Gutierrez O., Pons F., Crespo J., et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. J Biol Chem 2003, 278:5509-5512.
117. Philpott D.J., Girardin S.E. The role of Toll-like receptors and Nod proteins in bacterial infection. Mol Immunol 2004, 41:1099-1108.
118. Hasegawa M., Yamazaki T., Kamada N., Tawaratsumida K., Kim Y.G., Nunez G., et al. Nucleotide-binding oligomerization domain 1 mediates recognition of Clostridium difficile and induces neutrophil recruitment and protection against the pathogen. J Immunol 2011, 186:4872-4880.
119. Deshmukh H.S., Hamburger J.B., Ahn S.H., McCafferty D.G., Yang S.R., Fowler V.G. Critical role of NOD2 in regulating the immune response to Staphylococcus aureus. Infect Immun 2009, 77:1376-1382.
120. Hruz P., Zinkernagel A.S., Jenikova G., Botwin G.J., Hugot J.P., Karin M., et al. NOD2 contributes to cutaneous defense against Staphylococcus aureus through alpha-toxin-dependent innate immune activation. Proc Natl Acad Sci USA 2009, 106:12873-12878.
121. Clarke T.B., Davis K.M., Lysenko E.S., Zhou A.Y., Yu Y.M., Weiser J.N. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med 2010, 16:228-U137.
122. Yokoyama R., Itoh S., Kamoshida G., Takii T., Fujii S., Tsuji T., et al. Staphylococcal superantigen-like protein 3 binds to the Toll-like receptor 2 extracellular domain and inhibits cytokine production induced by Staphylococcus aureus, cell wall component, or lipopeptides in murine macrophages. Infect Immun 2012, 80:2816-2825.
123. Bardoel B.W., van Strijp J.A.G. Molecular battle between host and bacterium: recognition in innate immunity. J Mol Recognit 2011, 24:1077-1086.
124. Bardoel B.W., Vos R., Bouman T., Aerts P.C., Bestebroer J., Huizinga E.G., et al. Evasion of Toll-like receptor 2 activation by staphylococcal superantigen-like protein 3. J Mol Med 2012, 90:1109-1120.
125. Luft F.C. Staphylococcus aureus, Toll-like receptors, superantigens, and their derivatives. J Mol Med 2012, 90:1091-1093.
126. Miller L.S., Cho J.S. Immunity against Staphylococcus aureus cutaneous infections. Nat Rev Immunol 2011, 11:505-518.
127. Eriksen N.H.R., Espersen F., Rosdahl V.T., Jensen K. Carriage of Staphylococcus aureus among 104 healthy-persons during a 19-month period. Epidemiol Infect 1995, 115:51-60.
128. VandenBergh M.F.Q., Yzerman E.P.F., van Belkum A., Boelens H.A.M., Sijmons M., Verbrugh H.A. Follow-up of Staphylococcus aureus nasal carriage after 8 years: redefining the persistent carrier state. J Clin Microbiol 1999, 37:3133-3140.
129. Nouwen J.L., Ott A., Kluytmans-Vandenbergh M.F.Q., Boelens H.A.M., Hofman A., van Belkum A., et al. Predicting the Staphylococcus aureus nasal carrier state: derivation and validation of a culture rule. Clin Infect Dis 2004, 39:806-811.
130. Corrigan R.M., Miajlovic H., Foster T.J. Surface proteins that promote adherence of Staphylococcus aureus to human desquamated nasal epithelial cells. BMC Microbiol 2009, 9.
131. Hoffmann C., Ohlsen K., Hauck C.R. Integrin-mediated uptake of fibronectin-binding bacteria. Eur J Cell Biol 2011, 90:891-896.
132. Ythier M., Entenza J.M., Bille J., Vandenesch F., Bes M., Moreillon P., et al. Natural variability of in vitro adherence to fibrinogen and fibronectin does not correlate with in vivo infectivity of Staphylococcus aureus. Infect Immun 2010, 78:1711-1716.
133. Niemann S., Spehr N., Van Aken H., Morgenstern E., Peters G., Herrmann M., et al. Soluble fibrin is the main mediator of Staphylococcus aureus adhesion to platelets. Circulation 2004, 110:193-200.
134. Haim M., Trost A., Maier C.J., Achatz G., Feichtner S., Hintner H., et al. Cytokeratin 8 interacts with clumping factor B: a new possible virulence factor target. Microbiology-SGM 2010, 156:3710-3721.
135. Corrigan R.M., Rigby D., Handley P., Foster T.J. The role of Staphylococcus aureus surface protein SasG in adherence and biofilm formation. Microbiology-SGM 2007, 153:2435-2446.
136. Gomez M.I., O'Seaghdha M., Magargee M., Foster T.J., Prince A.S. Staphylococcus aureus protein A activates TNFR1 signaling through conserved IgG binding domains. J Biol Chem 2006, 281:20190-20196.
137. Smith E.J., Visai L., Kerrigan S.W., Speziale P., Foster T.J. The Sbi protein is a multifunctional immune evasion factor of Staphylococcus aureus. Infect Immun 2011, 79:3801-3809.
138. Kim H.K., Thammavongsa V., Schneewind O., Missiakas D. Recurrent infections and immune evasion strategies of Staphylococcus aureus. Curr Opin Microbiol 2012, 15:92-99.
139. Hair P.S., Echague C.G., Sholl A.M., Watkins J.A., Geoghegan J.A., Foster T.J., et al. Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis. Infect Immun 2010, 78:1717-1727.
140. Hair P.S., Ward M.D., Semmes O.J., Foster T.J., Cunnion K.M. Staphylococcus aureus clumping factor A binds to complement regulator factor I and increases factor I cleavage of C3b. J Infect Dis 2008, 198.
141. Jongerius I., Garcia B.L., Geisbrecht B.V., van Strijp J.A.G., Rooijakkers S.H.M. Convertase inhibitory properties of staphylococcal extracellular complement-binding protein. J Biol Chem 2010, 285:14973-14979.
142. Sharp J.A., Echague C.G., Hair P.S., Ward M.D., Nyalwidhe J.O., Geoghegan J.A., et al. Staphylococcus aureus surface protein SdrE Binds complement regulator factor H as an immune evasion tactic. PLoS ONE 2012, 7.
143. Haggar A., Flock J.I., Norrby-Teglund A. Extracellular adherence protein (Eap) from Staphylococcus aureus does not function as a superantigen. Clin Microbiol Infect 2010, 16:1155-1158.
144. DeDent A., Kim H.K., Missiakas D., Schneewind O. Exploring Staphylococcus aureus pathways to disease for vaccine development. Semin Immunopathol 2012, 34:317-333.
145. Mazzilli M., Zecconi A. Assessment of epithelial cells' immune and inflammatory response to Staphylococcus aureus when exposed to a macrolide. J Dairy Res 2010, 77:404-410.
146. Brogden K.A., Ackermann M., McCray P.B., Tack B.F. Antimicrobial peptides in animals and their role in host defences. Int J Antimicrob Agents 2003, 22:465-478.
147. Ganz T. Antimicrobial polypeptides. J Leukoc Biol 2004, 75:34-38.
148. Nakatsuji T., Gallo R.L. Antimicrobial peptides: old molecules with new ideas. J Invest Dermatol 2012, 132:887-895.
149. Hoffmann J.A., Kafatos F.C., Janeway C.A., Ezekowitz R.A.B. Phylogenetic perspectives in innate immunity. Science 1999, 284:1313-1318.
150. Zasloff M. Antimicrobial peptides in health and disease. N Engl J Med 2002, 347:1199-1200.
151. Brogden K.A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria. Nat Rev Microbiol 2005, 3:238-250.
152. Hancock R.E.W., Diamond G. The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol 2000, 8:402-410.
153. Hancock R.E.W., Scott M.G. The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci USA 2000, 97:8856-8861.
154. Jenssen H., Hamill P., Hancock R.E.W. Peptide antimicrobial agents. Clin Microbiol Rev 2006, 19:491.
155. Cederlund A., Gudmundsson G.H., Agerberth B. Antimicrobial peptides important in innate immunity. FEBS J 2011, 278:3942-3951.
156. Lai Y.P., Gallo R.L. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol 2009, 30:131-141.
157. Ganz T. Defensins: antimicrobial peptides of vertebrates. C R Biol 2004, 327:539-549.
158. Maier V.H., Schmitt C.N.Z., Gudmundsdottir S., Gudmundsson G.H. Bacterial DNA indicated as an important inducer of fish cathelicidins. Mol Immunol 2008, 45:2352-2358.
159. Zhao H., Gan T.X., Liu X.D., Jin Y., Lee W.H., Shen J.H., et al. Identification and characterization of novel reptile cathelicidins from elapid snakes. Peptides 2008, 29:1685-1691.
160. Xiao Y.J., Cai Y.B., Bommineni Y.R., Fernando S.C., Prakash O., Gilliland S.E., et al. Identification and functional characterization of three chicken cathelicidins with potent antimicrobial activity. J Biol Chem 2006, 281:2858-2867.
161. Daly K.A., Digby M.R., Lefevre C., Nicholas K.R., Deane E.M., Williamson P. Identification, characterization and expression of cathelicidin in the pouch young of tammar wallaby (Macropus eugenii). Comp Biochem Physiol B 2008, 149:524-533.
162. Scocchi M., Wang S.L., Zanetti M. Structural organization of the bovine cathelicidin gene family and identification of a novel member. FEBS Lett 1997, 417:311-315.
163. Wu H.A., Zhang G.L., Ross C.R., Blecha F. Cathelicidin gene expression in porcine tissues: roles in ontogeny and tissue specificity. Infect Immun 1999, 67:439-442.
164. Bruhn O., Grotzinger J., Cascorbi I., Jung S. Antimicrobial peptides and proteins of the horse - insights into a well-armed organism. Vet Res 2011, 42.
165. Gallo R.L., Kim K.J., Bernfield M., Kozak C.A., Zanetti M., Merluzzi L., et al. Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J Biol Chem 1997, 272:13088-13093.
166. Termen S., Tollin M., Olsson B., Svenberg T., Agerberth B., Gudmundsson G.H. Phylogeny, processing and expression of the rat cathelicidin rCRAMP: a model for innate antimicrobial peptides. Cell Mol Life Sci 2003, 60:536-549.
167. Sorensen O.E., Follin P., Johnsen A.H., Calafat J., Tjabringa G.S., Hiemstra P.S., et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001, 97:3951-3959.
168. Durr U.H.N., Sudheendra U.S., Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta-Biomembranes 2006, 1758:1408-1425.
169. Braff M.H., Hawkins M.A., Di Nardo A., Lopez-Garcia B., Howell M.D., Wong C., et al. Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J Immunol 2005, 174:4271-4278.
170. Turner J., Cho Y., Dinh N.N., Waring A.J., Lehrer R.I. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 1998, 42:2206-2214.
171. Agerberth B., Charo J., Werr J., Olsson B., Idali F., Lindbom L., et al. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000, 96:3086-3093.
172. Di Nardo A., Vitiello A., Gallo R.L. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol 2003, 170:2274-2278.
173. Ong P.Y., Ohtake T., Brandt C., Strickland I., Boguniewicz M., Ganz T., et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002, 347:1151-1160.
174. Cole A.M., Liao H.I., Stuchlik O., Tilan J., Pohl J., Ganz T. Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol 2002, 169:6985-6991.
175. Lehrer R.I., Ganz T. Cathelicidins: a family of endogenous antimicrobial peptides. Curr Opin Hematol 2002, 9:18-22.
176. Eckmann L. Defence molecules in intestinal innate immunity against bacterial infections. Curr Opin Gastroenterol 2005, 21:147-151.
177. Chromek M., Slamova Z., Bergman P., Kovacs L., Podracka L., Ehren I., et al. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat Med 2006, 12:636-641.
178. Masschalck B., Michiels C.W. Antimicrobial properties of lysozyme in relation to foodborne vegetative bacteria. Crit Rev Microbiol 2003, 29:191-214.
179. Masschalck B., Deckers D., Michiels C.W. Lytic and nonlytic mechanism of inactivation of Gram-positive bacteria by lysozyme under atmospheric and high hydrostatic pressure. J Food Prot 2002, 65:1916-1923.
180. Chen X.J., Niyonsaba F., Ushio H., Okuda D., Nagaoka I., Ikeda S., et al. Synergistic effect of antibacterial agents human beta-defensins, cathelicidin LL-37 and lysozyme against Staphylococcus aureus and Escherichia coli. J Dermatol Sci 2005, 40:123-132.
181. Kraus D., Peschel A. Staphylococcus aureus evasion of innate antimicrobial defense. Future Microbiol 2008, 3:437-451.
182. Li M., Lai Y.P., Villaruz A.E., Cha D.J., Sturdevant D.E., Otto M. Gram-positive three-component antimicrobial peptide-sensing system. Proc Natl Acad Sci USA 2007, 104:9469-9474.
183. Li M., Cha D.J., Lai Y.P., Villaruz A.E., Sturdevant D.E., Otto M. The antimicrobial peptide-sensing system aps of Staphylococcus aureus. Mol Microbiol 2007, 66:1136-1147.
184. Peschel A., Otto M., Jack R.W., Kalbacher H., Jung G., Gotz F. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem 1999, 274:8405-8410.
185. Peschel A., Jack R.W., Otto M., Collins L.V., Staubitz P., Nicholson G., et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med 2001, 193:1067-1076.
186. Kraus D., Herbert S., Kristian S.A., Khosravi A., Nizet V., Gotz F., et al. The GraRS regulatory system controls Staphylococcus aureus susceptibility to antimicrobial host defenses. BMC Microbiol 2008, 8.
187. Peschel A., Vuong C., Otto M., Gotz F. The d-alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes. Antimicrob Agents Chemother 2000, 44:2845-2847.
188. Ruzin A., Severin A., Moghazeh S.L., Etienne J., Bradford P.A., Projan S.J., et al. Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureus. Biochim Biophys Acta-Gen Subjects 2003, 1621:117-121.
189. Bera A., Herbert S., Jakob A., Vollmer W., Gotz F. Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O-acetyltransferase OatA is the major determinant for lysozyme resistance of Staphylococcus aureus. Mol Microbiol 2005, 55:778-787.
190. Jin T., Bokarewa M., Foster T., Mitchell J., Higgins J., Tarkowski A. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J Immunol 2004, 172:1169-1176.
191. Braff M.H., Jones A.L., Skerrett S.J., Rubens C.E. Staphylococcus aureus exploits cathelicidin antimicrobial peptides produced during early pneumonia to promote staphylokinase-dependent fibrinolysis. J Infect Dis 2007, 195:1365-1372.
192. Bokarewa M.I., Jin T., Tarkowski A. Staphylococcus aureus: staphylokinase. Int J Biochem Cell Biol 2006, 38:504-509.
193. Travis S.M., Anderson N.N., Forsyth W.R., Espiritu C., Conway B.D., Greenberg E.P., et al. Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun 2000, 68:2748-2755.
194. Sieprawska-Lupa M., Mydel P., Krawczyk K., Wojcik K., Puklo M., Lupa B., et al. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob Agents Chemother 2004, 48:4673-4679.
195. Ouhara K., Komatsuzawa H., Kawai T., Nishi H., Fujiwara T., Fujiue Y., et al. Increased resistance to cationic antimicrobial peptide LL-37 in methicillin-resistant strains of Staphylococcus aureus. J Antimicrob Chemother 2008, 61:1266-1269.
196. Wang G.S., Epand R.F., Mishra B., Lushnikova T., Thomas V.C., Bayles K.W., et al. Decoding the functional roles of cationic side chains of the major antimicrobial region of human cathelicidin LL-37. Antimicrob Agents Chemother 2012, 56:845-856.
197. Bestebroer J., Poppelier M.J.J.G., Ulfman L.H., Lenting P.J., Denis C.V., van Kessel K.P.M., et al. Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated neutrophil rolling. Blood 2007, 109:2936-2943.
198. Chavakis T., Hussain M., Kanse S.M., Peters G., Bretzel R.G., Flock J.I., et al. Staphylococcus aureus extracellular adherence protein serves as anti-inflammatory factor by inhibiting the recruitment of host leukocytes. Nat Med 2002, 8:687-693.
199. Walenkamp A.M.E., Boer I.G.J., Bestebroer J., Rozeveld D., Timmer-Bosscha H., Hemrika W., et al. Staphylococcal superantigen-like 10 inhibits CXCL12-induced human tumor cell migration. Neoplasia 2009, 11:333-344.
200. Ventura C.L., Malachowa N., Hammer C.H., Nardone G.A., Robinson M.A., Kobayashi S.D., et al. Identification of a novel Staphylococcus aureus two-component leukotoxin using cell surface proteomics. PLoS ONE 2010, 5:11.